Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of CTP-499 following single dose administration.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Concert Pharmaceuticals
• Treatments: Pentoxifylline

Criteria

Inclusion Criteria:

• healthy volunteers

• ages 18 to 55 years old

• nonsmokers

• BMI of 18 to 30 kg/m2

Exclusion Criteria:

• Significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders of drug hypersensitivity

• Systolic Blood pressure < 90 or > 140, diastolic bp > 90